Our study included 2792 participants, which consisted of 1090 males (38.7%) and 1712 females (61.3%). Among them, 2311 patients (82.9%) were married or living with a partner, 2209 patients (79.1%) had junior high school or below education level, 1735 patients (59.7%) did not smoke and 1915 patients (68.6%) did not drink alcohol. The basic characteristics of the participants are shown in Table 1.
Table 1
Basic characteristics of participants
Characteristic | Overall sample (N = 2792) |
mean | SD |
Age, year | 65.26 | 9.85 |
BMI, kg/m2 | 24.94 | 4.04 |
Sex (n + %) | | |
Male | 1080 | 38.7 |
Female | 1712 | 61.3 |
Marital status (n + %) | | |
Married or partnered | 2311 | 82.8 |
Separated, divorced, or widowed | 464 | 16.6 |
Never married | 17 | 0.6 |
Educational status (n + %) | | |
Junior high school or below | 2209 | 79.1 |
Senior high school or vocational school | 385 | 13.8 |
College or above | 198 | 7.1 |
Smoking (n + %) | | |
Never | 1735 | 62.1 |
Former | 480 | 17.2 |
Current | 572 | 20.5 |
Drinking (n + %) | | |
Never | 1915 | 68.6 |
Former | 146 | 5.2 |
Current | 731 | 26.2 |
Abbreviation: SD, standard deviation; BMI, Body Mass Index. |
Table 2 shows the relationship between frequency of PA and daily physical function. Compared with individuals taking no PA, individuals taking MPA and VPA with a frequency of 6–7 d/w had lower risks of impaired daily physical function (OR = 0.47, 95%CI: 0.25, 0.91; OR = 0.57, 95%CI: 0.37, 0.88). Furthermore, as the relationship between frequency of PA and cognitive function shows (Table 2), individuals with MPA 1-2d/w as well as 6-7d/w all had higher cognitive function scores (β = 1.51, 95%CI:0.02, 3.00; β = 1.22, 95%CI:0.42, 2.03), individuals with LPA 3-5d/w as well as 6-7d/w all had higher cognitive function scores (β = 2.06, 95%CI:0.75, 3.36; β = 1.08,95%CI:0.43, 1.73), while individuals taking VPA 3–5 d/w had lower scores of cognitive function (β= -1.96, 95%CI: -3.51, -0.40).
Table 2
Associations between PA and daily physical activity ability and cognitive function of patients with heart disease.
Variables | Daily Physical Function | Cognitive Function |
OR | 95% CI | β | 95% CI |
Frequency | | | | |
VPA | | | | |
No activity | 1.00 | | 1.00 | |
1-2d/w | N/A | N/A | -0.53 | -2.26, 1.20 |
3-5d/w | 1.48 | 0.43,5.11 | -1.96 | -3.51, -0.40 * |
6-7d/w | 1.09 | 0.41,2.90 | -0.92 | -2.03, 0.19 |
MPA | | | | |
No activity | 1.00 | | 1.00 | |
1-2d/w | 0.38 | 0.09,1.62 | 1.51 | 0.02, 3.00 * |
3-5d/w | 0.25 | 0.06,1.08 | 0.76 | -0.50, 2.01 |
6-7d/w | 0.47 | 0.25,0.91 * | 1.22 | 0.42, 2.03 ** |
LPA | | | | |
No activity | 1.00 | | 1.00 | |
1-2d/w | 1.59 | 0.53,4.79 | 0.80 | -1.18, 2.77 |
3-5d/w | 0.52 | 0.19,1.47 | 2.06 | 0.75, 3.36 ** |
6-7d/w | 0.57 | 0.37,0.88 * | 1.08 | 0.43, 1.73 ** |
Duration | | | | |
VPA | | | | |
No activity | 1.00 | | 1.00 | |
10–29 min/d | N/A | N/A | 0.58 | -3.05, 4.21 |
30–119 min/d | 0.79 | 0.18,3.43 | -1.06 | -2.72, 0.59 |
120–239 min/d | 0.98 | 0.23,4.27 | -1.29 | -2.86, 0.29 |
≥ 240 min/d | 0.97 | 0.32,2.99 | -0.99 | -2.22, 0.24 |
MPA | | | | |
No activity | 1.00 | | 1.00 | |
10–29 min/d | 0.51 | 0.15,1.67 | 1.78 | 0.34, 3.21 * |
30–119 min/d | 0.64 | 0.32,1.27 | 1.43 | 0.49, 2.37 ** |
120–239 min/d | 0.30 | 0.09,1.01 | 0.98 | -0.17, 2.13 |
≥ 240 min/d | N/A | N/A | 0.67 | -0.59, 1.93 |
LPA | | | | |
No activity | 1.00 | | 1.00 | |
10–29 min/d | 0.47 | 0.20,1.11 | 1.18 | -0.08, 2.29 * |
30–119 min/d | 0.59 | 0.36,0.97 * | 1.30 | 0.56, 2.04 ** |
120–239 min/d | 0.58 | 0.27,1.25 | 0.83 | -0.16, 1.82 |
≥ 240 min/d | 1.32 | 0.55,3.18 | 0.75 | -0.56, 2.06 |
Volume | | | | |
VPA | | | | |
No activity | 1.00 | | 1.00 | |
10–74 min/w | N/A | N/A | -0.66 | -5.60, 4.28 |
75–299 min/w | N/A | N/A | -0.71 | -2.74, 1.33 |
≥ 300 min/w | 1.06 | 0.45, 2.48 | -1.18 | -2.14, -0.23 * |
MPA | | | | |
No activity | 1.00 | | 1.00 | |
10–149 min/w | 0.57 | 0.22, 1.49 | 1.67 | 0.46, 2.87 ** |
150–299 min/w | 0.95 | 0.22, 4.15 | 2.02 | -0.18, 4.06 |
≥ 300 min/w | 0.35 | 0.17, 0.72 ** | 0.89 | 0.09, 1.68 * |
LPA | | | | |
No activity | 1.00 | | 1.00 | |
10–149 min/w | 0.64 | 0.31, 1.33 | 1.25 | 0.19, 2.30 * |
150–299 min/w | 0.27 | 0.04, 2.04 | 1.24 | -0.69, 3.16 |
≥ 300 min/w | 0.59 | 0.38, 0.92 * | 1.26 | 0.59, 1.93 ** |
Abbreviations: OR, odds ratio; β, Regression coefficients; CI, confidence interval; PA, physical activity; VPA, vigorous physical activity; MPA, moderate physical activity; LPA, light physical activity; Model was adjusted for age, sex, educational status, marital status, drinking, smoking, BMI; N/A denoted that no applicable value was observed; *: p < 0.05; **: p < 0.01. |
Table 2 shows the relationship between duration of PA and daily physical function. Compared with individuals taking no PA, no significance in risks of impaired daily physical function between MPA and VPA of any duration, whereas only individuals taking LPA with a duration of 30–119 min/d had lower risks of impaired daily physical function (OR = 0.59, 95%CI: 0.36, 0.97). Furthermore, as the relationship between duration of PA and cognitive function shows (Table 2), compared with individuals taking no PA, individuals with MPA 10–29 min/d as well as 30–119 min/d all had higher cognitive function scores (β = 1.78, 95%CI:0.34, 3.21; β = 1.43, 95%CI:0.49, 2.37), individuals with LPA 10–29 min/d as well as 30–119 min/d all had higher cognitive function scores (β = 1.18, 95%CI: -0.08, 2.29; β = 1.30, 95%CI: -0.56, 2.06).
Table 2 shows the relationship between volume of PA and daily physical function. Compared with individuals taking no PA, individuals taking MPA and LPA with a volume of ≥ 300 min/w had lower risks of impaired daily physical function (OR = 0.35, 95%CI: 0.17, 0.72; OR = 0.59, 95%CI: 0.38, 0.92), whereas no significance between VPA of any volume and risks of impaired daily physical function. Furthermore, as the relationship between volume of PA and cognitive function shows (Table 2), compared with individuals taking no PA, whereas lower scores of cognitive functions in volume of ≥ 300 min/w. (β= -1.18, 95%CI: -2.14, -0.23). a volume of 10–149 min/w, of ≥ 300 min/w in MPA (β = 1.67, 95%CI: 0.46, 2.87; β = 0.89, 95%CI: 0.09, 1.68) and LPA (β = 1.25, 95%CI: 0.19, 2.30; β = 1.26, 95%CI: 0.59, 1.93) all had higher cognitive function scores.
Table 3 shows the relationship between METs and daily physical function, cognitive function. Compared with individuals taking no PA, individuals taking 1800 to < 2999METs, 3000 to < 5999METs and 6000 to < 8999METs had lower risks of impaired daily physical function (OR = 0.18, 95%CI: 0.04, 0.75; OR = 0.29, 95%CI: 0.14, 0.60; OR = 0.24, 95%CI: 0.08, 0.77) and higher cognitive function scores (β = 2.94, 95%CI: 1.67, 4.21; β = 1.23, 95%CI: 0.40, 2.06; β = 1.32, 95%CI: 0.21, 2.43). Furthermore, Individuals with 1800–2999 METs had lowest risks of impaired daily physical function and highest scores of cognitive functions. (OR = 0.18, 95%CI: 0.04, 0.75; β = 2.94, 95%CI: 1.67, 4.21).
Table 3
Associations between Mets and the daily physical activity ability and cognitive function of patients with heart disease.
Variables | Daily Physical Function | Cognitive Function |
OR | 95% CI | β | 95% CI |
Mets | | | | |
0 to < 600 | | | | |
600 to < 1199 | 0.31 | 0.07, 1.31 | 1.28 | -0.49, 3.05 |
1200 to < 1799 | 0.60 | 0.34, 1.06 | 1.29 | 0.317, 2.26 ** |
1800 to < 2999 | 0.18 | 0.04, 0.75 * | 2.94 | 1.67, 4.21 ** |
3000 to < 5999 | 0.29 | 0.14, 0.60 ** | 1.23 | 0.40, 2.06 ** |
6000 to < 8999 | 0.24 | 0.08, 0.77 * | 1.32 | 0.21, 2.43 * |
9000 to < 11999 | 0.29 | 0.07, 1.19 | 0.71 | -0.75, 2.17 |
≥ 12,000 | 0.42 | 0.17, 1.04 | 0.98 | -0.10, 2.05 |
Abbreviations: OR, odds ratio; β, Regression coefficients; CI, confidence interval; Model was adjusted for age, sex, educational status, marital status, drinking, smoking, and BMI; *: p < 0.05; **: p < 0.01. |